StockNews.com Initiates Coverage on Cytosorbents (NASDAQ:CTSO)

Equities researchers at StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO - Get Free Report) in a note issued to investors on Saturday. The brokerage set a "hold" rating on the medical research company's stock.

Several other research analysts have also issued reports on the company. D. Boral Capital reiterated a "buy" rating and set a $10.00 price objective on shares of Cytosorbents in a research note on Monday, January 13th. HC Wainwright reiterated a "neutral" rating and set a $1.00 price objective on shares of Cytosorbents in a research note on Monday, November 11th. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $4.67.

Cytosorbents Price Performance

Shares of CTSO stock opened at $1.15 on Friday. The stock has a market cap of $62.88 million, a P/E ratio of -3.19 and a beta of 0.61. Cytosorbents has a one year low of $0.70 and a one year high of $1.61. The stock has a fifty day moving average price of $1.01 and a 200 day moving average price of $1.04. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58.

Hedge Funds Weigh In On Cytosorbents

Several hedge funds have recently added to or reduced their stakes in CTSO. Millennium Management LLC bought a new position in Cytosorbents during the fourth quarter worth about $30,000. Renaissance Technologies LLC lifted its holdings in shares of Cytosorbents by 10.6% during the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company's stock valued at $80,000 after purchasing an additional 8,400 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Cytosorbents by 22.3% during the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock valued at $83,000 after purchasing an additional 16,701 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Cytosorbents during the 4th quarter valued at about $99,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock valued at $701,000 after purchasing an additional 32,415 shares in the last quarter. Institutional investors own 32.87% of the company's stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.